Amicus Therapeutics FOLD NASDAQ · Healthcare · United States
$14.49 +0.00% +$0.00
Summary
24 / 100 · Bulios Score
What speaks for it
- Revenue grew by 15% a year over the last 3 years.
- The price moves less than the market (beta 0.48).
What to watch
- The company made a loss over the last 12 months.
- Operating profit does not even cover the interest on its debt.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
- Analyst estimate
Revenue grew by 19% a year over 5 years. Over the last 3 years it grew by 15% a year.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
YesIt holds more cash than debt. The debt score is low because of the debt-to-equity ratio (1.6x).
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 16
- Hold 7
- Sell 1
No analyst has published a price target.
67% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
This revenue breakdown is on the way.
By region
This revenue breakdown is on the way.